While escalating drug prices continues to a hot-button topic in the United States,Pfizer Inc. has speed into trouble over the pricing of an epilepsy medicine in Europe.
On Wednesday, the United Kingdom’s Competition and Markets Authority (CMA) hit Pfizer with a $107 million fine tied to the hiking of the price of Epanutin by as much as 2600 percent between 2013 and 2012.
The CMA also imposed a $5.6 million fine on Flynn Pharma. Pfizer sold the U.
K. distribution rights for Epanutin to Flynn in…
Source: bizjournals.com